Shots:

• The companies extend their existing collaboration to evaluate Immunomedics’ Trodelvy (sacituzumab govitecan-hziy) in combination with Tecentriq (atezolizumab) in patients with mUC and mNSCLC. The partners have ongoing collaboration in 1L metastatic triple-negative BC
• Roche will conduct two P-Ib/II studies utilizing MORPHEUS platform. The MORPHEUS-mUC study will evaluate Tecentriq + Trodelvy vs Tecentriq as monothx. in CPI-naïve mUC patients who have failed platinum-containing CT while Morpheus-Lung will evaluate the combination therapy vs docetaxel in CPI-experienced mNSCLC patients after failure with a platinum-based regimen
• Additionally- Immunomedics has initiated enrollment in its P-II NeoSTAR study in neoadjuvant triple-negative BC with the expecting 1EPs as CRR and disease-free survival and OS serving as 2EPs

Click here to­ read full press release/ article 

Ref: PRNewswire | Image: Roche